查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1420415

全球帶狀皰疹疫苗市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按產品類型、按免疫類型、按地區

Shingles Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 250 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

全球帶狀皰疹疫苗市場正在經歷顯著成長，預計到 2024 年將達到約 46 億美元。預計未來 10 年該市場將以 16% 的複合年增長率成長，到 2031 年底將達到 130 億美元。

國家生物技術資訊中心強調帶狀皰疹疫苗在預防帶狀皰疹傳播方面的關鍵作用。現有的針對帶狀皰疹後神經痛（PHN）的抗病毒治療並不完全有效，特別是對於免疫功能低下的患者，這增加了疫苗開發的緊迫性。

由於免疫系統較弱，60歲以上的老年人特別容易感染帶狀皰疹。美國疾病管制與預防中心 (CDC) 報告稱，全球帶狀皰疹病例中有一半發生在這個年齡段，這凸顯了對安全且具有成本效益的帶狀皰疹疫苗的需求。雖然帶狀皰疹並不致命，但它可能導致肺炎和腦炎等健康併發症，因此疫苗對該族群至關重要。

帶狀皰疹的盛行率因地區和氣候條件而異。帶狀皰疹由水痘帶狀皰疹病毒引起，在熱帶和亞熱帶地區很常見。欠發達國家，特別是熱帶亞洲國家，缺乏常規水痘疫苗接種，這為帶狀皰疹疫苗市場創造了機會。將帶狀皰疹疫苗接種規劃納入世衛組織區域免疫戰略計劃，可以顯著減輕欠發達地區的疾病負擔和相關併發症。

本報告研究了全球帶狀皰疹疫苗市場，並提供了市場概況，包括按產品類型、免疫類型、區域趨勢以及進入市場的公司的競爭趨勢劃分的趨勢。

目錄

第一章執行摘要

第二章市場概況

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • COVID-19 影響分析
  • 烏克蘭與俄羅斯衝突的影響
  • 經濟概況
  • PESTLE分析

第三章 2018-2031年全球帶狀皰疹疫苗市場展望

  • 全球帶狀皰疹疫苗市場展望，按產品類型、價值（十億美元），2018-2031 年
  • 全球帶狀皰疹疫苗市場展望，按免疫類型、價值（十億美元），2018-2031
  • 全球帶狀皰疹疫苗市場展望，按地區，價值（十億美元），2018-2031

第四章 2018-2031 年北美帶狀皰疹疫苗市場展望

第五章歐洲帶狀皰疹疫苗市場展望，2018-2031

第六章 2018-2031 年亞太地區帶狀皰疹疫苗市場展望

第七章 2018-2031 年拉丁美洲帶狀皰疹疫苗市場展望

第八章 2018-2031 年中東和非洲帶狀皰疹疫苗市場展望

第9章 競爭格局

  • 按產品和疫苗接種類型劃分的熱圖
  • 2023 年公司市場份額分析
  • 比賽儀表板
  • 公司簡介
    • GlaxoSmithKline plc.
    • Merck & Co., Inc.
    • SK Chemicals
    • Green Cross Corp
    • Geneone Life Science
    • Vaccitech
    • CanSinoBIO
    • Cipla Inc.
    • Pfizer Inc

第10章附錄

簡介目錄

The global Shingles Vaccine market is experiencing significant growth, with a valuation of approximately US$ 4.6 billion in 2024. According to the latest report by Fairfield Market Research, the market is poised to achieve a staggering CAGR of 16% over the next decade, reaching an estimated US$ 13 billion by the end of 2031.

Sales Analysis and Market Outlook

Fairfield Market Research reveals that the Shingles vaccine segment exhibited the highest revenue share during the forecasted period. The recombinant vaccine, within the vaccine type segment, dominated with an impressive growth rate CAGR over the forecasted period.

The National Center for Biotechnology Information emphasizes the pivotal role of Shingles vaccines in preventing the prevalence of herpes zoster, with an estimated 278 million cases expected globally in the coming decade in the absence of effective vaccination. The urgency for vaccine development is heightened, especially for immunocompromised patients, as existing antiviral treatments are not entirely effective for postherpetic neuralgia (PHN).

Shingles among Older Adults Driving Market Demand

Older adults, particularly those aged 60 and above, face an increased susceptibility to shingles due to weakened immune systems. The Centers for Disease Control and Prevention (CDC) reports that half of all shingles cases worldwide occur in this age group, emphasizing the need for a safe and cost-effective herpes zoster vaccine. Shingles, while not deadly, can lead to health complications such as pneumonia and encephalitis, making a vaccine crucial for this demographic.

Shingles Market Dynamics in Underdeveloped Countries

The prevalence of shingles varies based on geographical regions and prevailing climatic conditions. Shingles caused by the Varicella Zoster virus is common in tropical and subtropical regions. Underdeveloped countries, particularly in tropical Asia, lack routine varicella vaccination, presenting an opportunity for the shingles vaccine market. Integrating shingles vaccination programs into the WHO Regional Strategic Plan for Immunization in underdeveloped regions could significantly reduce disease burdens and associated complications.

Challenges and Impact of COVID-19 on Shingles Vaccine Market

Despite the positive outlook, challenges persist in developing effective shingles vaccines. The vaccine is typically administered before exposure to the Varicella Zoster virus, requiring strategic planning for efficacy. The latent reactivation of the virus in individuals with pre-existing immunity poses a challenge, necessitating the development of therapeutic vaccines for prompt immune response.

The COVID-19 pandemic had mixed effects on the Shingles vaccine market. Supply tensions and export bans initially disrupted vaccine rollouts, affecting sales. GlaxoSmithKline reported a significant drop in sales in the first quarter of 2021, attributed to disruptions caused by COVID-19 vaccine rollouts. However, the market rebounded in 2022, with GlaxoSmithKline's Shingles vaccine witnessing high revenue, reflecting a strong demand that outpaced supply after the pandemic.

Regional Growth and Market Analysis

Europe is emerging as a key growth region for the Shingles vaccine market, with the U.K. leading the way. The U.K. approved the shingles vaccine in its immunization program, achieving a vaccination rate of approximately 60%. Initiatives by key vaccine companies, such as GlaxoSmithKline plc., are contributing to the market's momentum. The expected growth rate in the European shingles market is estimated at 17% from 2024 to 2031, with an absolute dollar opportunity growth by 2032.

Country-Specific Insights

South Korea: The shingles vaccine market in South Korea is valued significantly in 2031. Revenue from shingles vaccines witnessed a substantial growth rate over the period from 2018 to 2023. Korean companies are actively expanding their presence in the global market with their shingles vaccines. Despite entering the shingles vaccine market relatively late, South Korea has achieved remarkable success, becoming the world's second-largest vaccine producer. SK Bioscience introduced Sky Zoster as a global solution for treating herpes zoster. SK Bioscience has also initiated efforts for the approval of 'Sky Zoster' in South Asian countries and is actively engaged in global clinical trials and expanding its product reach in the United States, China, and Europe. South Korea is expected to experience significant absolute dollar opportunity growth in the shingles vaccine market between 2024 and 2031.

China: China plays a prominent role in the shingles vaccine market, following the United States. The market in China holds substantial value in 2031 and is projected to witness substantial absolute dollar opportunity growth during the forecasted period. China achieved a notable growth rate in the shingles vaccine market from 2018 to 2023.

Competitive Analysis:

The competitive landscape showcases strategic developments by key players, positioning them for continued success in the dynamic vaccine market.

Key Companies Profiled

  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • SK Chemicals
  • Green Cross Corp
  • Geneone Life Science
  • Vaccitech
  • CanSinoBIO
  • Cipla Inc.
  • Pfizer Inc

Diverse Segments Explored in Comprehensive Shingles Vaccine Industry Study

Shingles Vaccine Market by Product Type:

  • Shingles
  • Zostavax
  • Sky Zoster

Shingles Vaccine Market by Vaccine Type:

  • Recombinant Vaccine
  • Live Attenuated Vaccine

Shingles Vaccine Market by Region:

  • North America Shingles Vaccine Market
  • Latin America Shingles Vaccine Market
  • Europe Shingles Vaccine Market
  • South Asia Shingles Vaccine Market
  • East Asia Shingles Vaccine Market
  • Oceania Shingles Vaccine Market
  • Middle East & Africa Shingles Vaccine Market

Table of Contents

1. Executive Summary

  • 1.1. Global Shingles Vaccine Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Shingles Vaccine Market Outlook, 2018 - 2031

  • 3.1. Global Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Shingles
      • 3.1.1.2. Zostavax
      • 3.1.1.3. Sky Zoster
  • 3.2. Global Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Recombinant Vaccine
      • 3.2.1.2. Live Attenuated Vaccine
  • 3.3. Global Shingles Vaccine Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Shingles Vaccine Market Outlook, 2018 - 2031

  • 4.1. North America Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Shingles
      • 4.1.1.2. Zostavax
      • 4.1.1.3. Sky Zoster
  • 4.2. North America Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Recombinant Vaccine
      • 4.2.1.2. Live Attenuated Vaccine
  • 4.3. North America Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Shingles Vaccine Market Outlook, 2018 - 2031

  • 5.1. Europe Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Shingles
      • 5.1.1.2. Zostavax
      • 5.1.1.3. Sky Zoster
  • 5.2. Europe Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Recombinant Vaccine
      • 5.2.1.2. Live Attenuated Vaccine
  • 5.3. Europe Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Shingles Vaccine Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Shingles
      • 6.1.1.2. Zostavax
      • 6.1.1.3. Sky Zoster
  • 6.2. Asia Pacific Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Recombinant Vaccine
      • 6.2.1.2. Live Attenuated Vaccine
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Shingles Vaccine Market Outlook, 2018 - 2031

  • 7.1. Latin America Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Shingles
      • 7.1.1.2. Zostavax
      • 7.1.1.3. Sky Zoster
  • 7.2. Latin America Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Recombinant Vaccine
      • 7.2.1.2. Live Attenuated Vaccine
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Shingles Vaccine Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Shingles
      • 8.1.1.2. Zostavax
      • 8.1.1.3. Sky Zoster
  • 8.2. Middle East & Africa Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Recombinant Vaccine
      • 8.2.1.2. Live Attenuated Vaccine
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Product vs by Vaccination Type Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. GlaxoSmithKline plc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Therapy Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Merck & Co., Inc.
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Therapy Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. SK Chemicals
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Therapy Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Green Cross Corp
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Therapy Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Geneone Life Science
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Therapy Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Vaccitech
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Therapy Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. CanSinoBIO
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Therapy Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Cipla Inc.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Therapy Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Pfizer Inc
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Therapy Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations